Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02366819 · ClinicalTrials.gov registry record · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
A Phase 4 study of Gastric Adenocarcinoma and Esophageal Adenocarcinoma, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 3
- Study locations
NCT02366819 is a Phase 4 study of Gastric Adenocarcinoma and Esophageal Adenocarcinoma that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 36 participants, below the 245-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT02366819, a Phase 4 study of Gastric Adenocarcinoma and Esophageal Adenocarcinoma, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 3
- Study locations
Study Summary
This pilot clinical trial studies genetic analysis-guided irontecan hydrochloride dosing of modified fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin (mFOLFIRINOX) in treating patients with gastroesophageal or stomach cancer that has spread from where it started to nearby tissue or lymph nodes. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, leucovorin calcium, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin calcium may also help fluorouracil work better. Genetic analysis may help doctors determine what dose of irinotecan hydrochloride patients can tolerate.
Conditions Studied
Interventions
- DRUG Fluorouracil
- DRUG Oxaliplatin
- DRUG Irinotecan Hydrochloride
- DRUG Leucovorin Calcium
- PROCEDURE Conventional Surgery
Study Locations (3)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
- Kellogg Cancer Center - Evanston Hospital - Evanston
- NorthShore University HealthSystem - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-12-11 |
| Est. Completion | 2026-06-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02366819
The ClinicalTrials.gov registry entry for NCT02366819 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (85% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Fluorouracil is the first listed.
NCT02366819 reports 3 study locations spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02366819 about?
NCT02366819 is a clinical study titled "Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer". This pilot clinical trial studies genetic analysis-guided irontecan hydrochloride dosing of modified fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin (mFOLFIRINOX) in treating patients with gastroesophageal or stomach cancer that has spread from where it started to nearby tiss...
What is the current status of trial NCT02366819?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2014-12-11. Estimated completion is 2026-06-08.
What conditions does trial NCT02366819 study?
This clinical trial studies the following conditions: Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Stage IIIB Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Adenocarcinoma.
What interventions are being tested in trial NCT02366819?
The interventions under investigation include: Fluorouracil (DRUG), Oxaliplatin (DRUG), Irinotecan Hydrochloride (DRUG), Leucovorin Calcium (DRUG), Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT02366819?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02366819 being conducted?
This trial has 3 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
RECRUITING · Phase 2
-
A Study Collecting Health Information to Understand and Prevent Gastric Cancer
RECRUITING
-
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
RECRUITING · Phase 2
-
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
RECRUITING · Phase 1
-
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.